As flagged with the trading statement, Diaceutics reported a 40% YoY increase in revenue to £19.5m generating EBITDA of £3.6m, up 53% YoY with diluted EPS of 0.84p, up 27% YoY. More important in our view, was the structural change in revenue generation to a recurring revenue model with platform-based subscription contracts accounting for 35% of revenue up from 3% in 2021, driving the development of a meaningful forward order book of £16.9m (FY21 £1.7m) for the first time. Cash and net cash ended ....
17 Apr 2023
Diaceutics - FY22 Results - April 2023
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Diaceutics - FY22 Results - April 2023
Diaceutics Plc (DXRX:LON) | 104 0.5 0.5% | Mkt Cap: 87.7m
- Published:
17 Apr 2023 -
Author:
Colin Smith -
Pages:
7
As flagged with the trading statement, Diaceutics reported a 40% YoY increase in revenue to £19.5m generating EBITDA of £3.6m, up 53% YoY with diluted EPS of 0.84p, up 27% YoY. More important in our view, was the structural change in revenue generation to a recurring revenue model with platform-based subscription contracts accounting for 35% of revenue up from 3% in 2021, driving the development of a meaningful forward order book of £16.9m (FY21 £1.7m) for the first time. Cash and net cash ended ....